Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
2 Beaten-Down Growth Stocks to Buy in April
09:45am, Thursday, 20'th Apr 2023
Axsome is expecting important developments that should improve its already-bright prospects. Tandem's innovative insulin pump should allow it to capture a larger share of the diabetes market.
1 Risky Growth Stock Wall Street Says Is Poised for a 47% Rally
06:20am, Thursday, 20'th Apr 2023
Axsome just launched two treatments, Sunosi and Auvelity, and it could launch two others soon. It will take a while for sales to ramp up, and for the company to turn a profit.
Could Axsome Therapeutics Stock Help You Become a Millionaire?
08:30am, Sunday, 16'th Apr 2023
Axsome Therapeutics stock has generated significant gains over the past year. Analysts still see much more upside thanks to the biotech's growth potential.
Better Growth Stock: Axsome vs. CRISPR Therapeutics
05:30am, Sunday, 16'th Apr 2023
Axsome last year launched two products that could bring in revenue of more than $1 billion each. CRISPR Therapeutics recently completed regulatory requests for its first potential product.
Is It Too Late to Buy Axsome Therapeutics Stock?
10:15am, Saturday, 15'th Apr 2023
Axsome's stock trounced the market over the last 12 months. The biotech is ramping up sales of two recently approved therapies.
Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
07:00am, Friday, 14'th Apr 2023
NEW YORK, April 14, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste
Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8
07:00am, Thursday, 13'th Apr 2023
Axsome to host conference call and webcast on Monday, May 8, 2023, at 8:00 a.m. Eastern Time Axsome to host conference call and webcast on Monday, May 8, 2023, at 8:00 a.m. Eastern Time
These Up-and-Coming Stocks Are Screaming Buys Right Now
05:30am, Thursday, 13'th Apr 2023
Axsome launched its first products last year -- and others may be on the horizon. CRISPR recently completed regulatory submissions for a blood disorder candidate with blockbuster potential.
Can Axsome Hold Out Till Depression Drug Becomes a Blockbuster?
08:35am, Wednesday, 12'th Apr 2023
Auvelity, a drug newly approved for major depressive disorder, could exceed $1 billion in sales by 2029. Analysts still expect Axsome to lose money through 2023 as its ambitious and extensive drug dev
A New Nasdaq Bull Market Is Nearly Here: 3 Stocks to Buy Sooner Rather Than Later
05:52am, Saturday, 08'th Apr 2023
Axsome Therapeutics has multiple catalysts on the way. MercadoLibre is already in a bull market of its own and has tremendous growth opportunities in Latin America.
Has Axsome Therapeutics Become a No-Brainer Buy?
09:45am, Wednesday, 05'th Apr 2023
Axsome's revenue topped $50 million last year as Sunosi and Auvelity gave the biotech some momentum. The company believes its cash position will sustain it until the business is generating positive ca
Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
03:53pm, Tuesday, 04'th Apr 2023
Two economic reports point to a possible recession later this year. Investors sold off risky biotech stocks as a result.
3 Surprisingly Underrated Stocks to Buy in April
06:14am, Saturday, 01'st Apr 2023
Axsome Therapeutics has multiple catalysts on the way. Johnson & Johnson is a bargain with its improving growth prospects.
The 3 Best Growth Stocks to Buy in the Biotech Sector
10:23pm, Wednesday, 29'th Mar 2023
Investors may want to keep an eye on biotech growth stocks, which are typically associated with the risk-on trade. Case in point: The sector ran up in January, but when the broader-market rally fizzle
3 Up-and-Coming Growth Stocks to Buy Right Now
06:00am, Saturday, 25'th Mar 2023
Axsome already has two approved drugs and could add two more in the near future. Sarepta has significant growth opportunities with its rare-disease drugs.
